FrancophonIA/ELRC3.0 huggingface dataset:
English: For CAPS, Kineret has been studied in one main study involving 43 patients with neonatal-onset multisystem inflammatory disease (NOMID/CINCA syndrome, the most severe form of CAPS).
Estonian: CAPS-sündroomide ravis uuriti Kinereti ühes põhiuuringus, milles osales 43 neonataalse tekkega multisüsteemse põletikulise haigusega (NOMID/CINCA-sündroom, raskeim CAPS-sündroomide vorm) patsienti.
English: By attaching to the receptors that interleukin 1 would normally attach itself to, anakinra blocks the activity of interleukin 1, helping to relieve the symptoms of these diseases.
Estonian: Anakinra seondub retseptoritega, millega tavaliselt seondub interleukiin-1, ning blokeerib sel viisil interleukiin-1 toime, leevendades haiguste sümptomeid.
English: For the full list of side effects of Kineret, see the package leaflet.
Estonian: Kinereti kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Results showed a significant and rapid improvement in symptoms, with a fall in average symptom score from 4.5 to 0.8 within 3 days of starting treatment.
Estonian: Uuringus tõendati sümptomite olulist ja kiiret leevenemist3 päeva jooksul ravi alustamisest vähenes keskmine sümptomite skoor 4,5-lt 0,8-le.
English: For Still's disease, three small studies have been carried out.
Estonian: Stilli tõve ravi näidustust uuriti kolmes väiksemas uuringus.
English: The active substance in Kineret, anakinra, is an immunosuppressive medicine (a medicine that reduces the activity of the immune system).
Estonian: Kinereti toimeaine anakinra on immuunsupressant (aine, mis pärsib immuunsüsteemi talitlust).
English: Kineret must not be used in people who are hypersensitive (allergic) to anakinra, to any of the other ingredients, or to proteins produced by Escherichia coli (a type of bacterium).
Estonian: Kinereti ei tohi kasutada patsiendid, kes on anakinra, selle ravimi mis tahes muu koostisaine või bakteri Escherichia coli toodetud valkude suhtes ülitundlikud (allergilised).
English: After one month of treatment, more patients on Kineret (6 out of 12 patients) achieved remission compared with treatment with DMARD (3 out of 10 patients).
Estonian: Pärast üht ravikuud oli remissiooniga patsiente rohkem Kinereti rühmas (6 patsienti 12-st) kui HMARR-rühmas (3 patsienti 10-st).
English: Given the beneficial effect and the fact that there were no new safety concerns, the Agency also considered that the benefits outweighed the risks in patients with CAPS and Still's disease.
Estonian: Arvestades kasulikku toimet ja uute ohutusprobleemide puudumist, oli amet arvamusel, et CAPS-sündroomide ja Stilli tõvega patsientidel on ravimi kasulikkus suurem kui riskid.
English: The active substance in Kineret, anakinra, is a copy of a natural human protein called ‘human interleukin 1 receptor antagonist'.
Estonian: Kinereti toimeaine anakinra on inimese loodusliku valgu, inimese interleukiin-1 retseptori antagonisti analoog.
English: It blocks the receptors for a chemical messenger in the body called interleukin 1.
Estonian: See blokeerib organismis keemilise virgatsaine interleukiin-1 retseptoreid.
English: In patients with severely reduced kidney function the doctor should consider giving Kineret every other day
Estonian: Raske neerukahjustusega patsientidel peab arst kaaluma Kinereti manustamist ülepäeviti.
English: It is used in combination with methotrexate (a medicine used to reduce inflammation) in patients who have not responded adequately to methotrexate alone;
Estonian: Seda kasutatakse koos metotreksaadiga (põletikku vähendav ravim) patsientidel, kellel ei ole metotreksaadi kasutamisel ainsa ravimina tekkinud piisavat ravivastust.
English: Kineret is a medicine that is used to treat:
Estonian: Kineret on ravim, mida kasutatakse järgmistel näidustustel.
English: This leads to inflammation in many parts of the body, with symptoms such as fever, rash, joint pain and tiredness.
Estonian: Seetõttu tekib organismis põletik, mille sümptomid on näiteks palavik, lööve, liigesevalu ja väsimus.
English: Severe disabilities such as deafness and loss of vision may also occur;
Estonian: Võib tekkida ka raske puue, näiteks kurtus või nägemiskaotus.
English: For CAPS and Still's disease, the dose depends on body weight and for CAPS, on the severity of the condition.
Estonian: CAPS-sündroomide ja Stilli tõve korral sõltub annus kehakaalust ja CAPS-sündroomide korral haigusseisundi raskusastmest.
English: Kineret must not be started in patients who have neutropenia (low levels neutrophils, a type of blood cell that fights infection).
Estonian: Kineret-ravi ei tohi alustada neutropeeniaga (neutrofiilide ehk infektsioonidega võitlevate valgevereliblede vähesus) patsientidel.
English: How does Kineret work?
Estonian: Kuidas Kineret toimib?
English: The European Medicines Agency decided that Kineret's benefits are greater than its risks for the treatment of the signs and symptoms of rheumatoid arthritis in combination with methotrexate, in patients with an inadequate response to methotrexate alone.
Estonian: Euroopa Ravimiamet otsustas, et Kinereti kasulikkus reumatoidartriidi nähtude ja sümptomite ravis koos metotreksaadiga patsientidel, kellel ei teki üksnes metotreksaadi kasutamisel piisavat ravivastust, on suurem kui sellega kaasnevad riskid.
English: adult patients who also received corticosteroids for their disease.
Estonian: Kolmandas uuringus osales 22 täiskasvanud patsienti, kes said haiguse raviks ka kortikosteroide.
English: What benefits of Kineret have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kinereti kasulikkus?
English: A second study in 24 children showed similar results: 67 % had at least a 30% reduction in symptoms after one month compared with 8 % given placebo.
Estonian: Teises uuringus, milles osales 24 last, olid sarnased tulemused: ühe kuu järel täheldas vähemalt 30% sümptomite vähenemist 67% Kinereti kasutanud patsientidest ja 8% platseebot kasutanud patsientidest.
English: • Still's disease, a disease causing inflammation of joints as well as rash and fever.
Estonian: • Stilli tõve (haigus, mis põhjustab liigesepõletikku ning ka löövet ja palavikku) ravi.
English: • signs and symptoms of rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults.
Estonian: • Reumatoidartriidi (liigesepõletikku põhjustav immuunsüsteemi haigus) nähtude ja sümptomite ravi täiskasvanutel.
English: The injection site should be varied with each dose to avoid discomfort.
Estonian: Ebamugavustunde vältimiseks tuleb valida iga annuse süstimiseks uus koht.
English: An overview of Kineret and why it is authorised in the EU
Estonian: Ülevaade ravimist Kineret ja ELis müügiloa väljastamise põhjendus
English: CAPS are a group of diseases where patients have a defect in the gene that produces a protein called cryopyrin.
Estonian: CAPS-sündroomid on haiguste rühm, mille korral on patsiendil valgu krüopüriini teket reguleeriv geen defektne.
English: This messenger is produced in high levels in patients with rheumatoid arthritis, causing inflammation of the joints and joint damage, and is also involved in the inflammation associated with CAPS and Still's disease.
Estonian: Reumatoidartriidiga patsientide organismis tekib seda virgatsainet suurel hulgal, mis põhjustab liigesepõletikku ja -kahjustusi ning CAPS-sündroomide ja Stilli tõvega seotud põletikku.
English: In the study using a fixed dose of Kineret, 38% of the patients adding Kineret had at least a 20% reduction in symptoms after six months, compared with 22% of those adding placebo.
Estonian: Kinereti püsiannusega uuringus oli patsiente, kelle sümptomid vähenesid kuue kuu möödudes vähemalt 20%, Kinereti kasutanud patsientide rühmas 38% ja platseeborühmas 22%.
English: In the first study, 11 of 15 children with Still's disease (73 %) had at least a 30% reduction in symptoms after three months treatment with Kineret.
Estonian: Esimeses uuringus täheldati 3-kuulise Kineret-ravi järel sümptomite vähemalt 30% vähenemist 11 Stilli tõvega lapsel 15-st (73%).
English: Kineret is available as a solution for injection under the skin.
Estonian: Kinereti turustatakse naha alla süstitava lahusena.
English: For CAPS and Still's disease, Kineret is used in patients from 8 months of age and weighing at least 10 kg. Kineret contains the active substance anakinra.
Estonian: CAPS-sündroomide ja Stilli tõve ravis kasutatakse Kinereti vähemalt 8 kuu vanustel patsientidel kehakaaluga vähemalt 10 kg.
English: Kineret should be used with caution in patients who have severely reduced liver function or moderately reduced kidney function.
Estonian: Raske maksakahjustusega või mõõduka neerukahjustusega patsiendid peavad Kinereti kasutama ettevaatlikult.
English: In addition levels of amyloid A, a marker of inflammation were also reduced.
Estonian: Patsientidel vähenes ka Aamüloidi sisaldus (teatav põletikumarker).
English: Results showed that Kineret was more effective than placebo when used as an add-on to methotrexate.
Estonian: Tulemustest nähtus, et koos metotreksaadiga kasutamisel oli Kineret platseebost efektiivsem.
English: Patients either received Kineret or another type of medicine, called a DMARD.
Estonian: Patsiendid kasutasid kas Kinereti või haigust modifitseerivat antireumaatilist ravimit (HMARR).
English: Kineret can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of rheumatoid arthritis, CAPS or Still's disease as appropriate.
Estonian: Ravi tohib alustada kas reumatoidartriidi, CAPS-sündroomide või Stilli tõve ravis kogenud arst ning see peab toimuma tema järelevalve all.
English: Children and Adolescents (aged 1 month to 17 years):
Estonian: Lapsed ja noorukid (vanuses 1 kuu kuni 17 aastat):
English: Date of first authorisation: 08 April 2016
Estonian: Müügiloa esmase väljastamise kuupäev:08. aprill 2016
English: • if you have other heart problems;
Estonian: • kui teil on muid südamehäireid;
English: Children and Adolescents:
Estonian: Lapsed ja noorukid:
English: 97.5 % CI
Estonian: 97,5% usaldusvahemik
English: • if you are allergic to palonosetron or any of the other ingredients of this medicine (listed in section 6).
Estonian: • kui olete palonosetrooni või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: • change in the colour of the vein and/or veins becoming larger
Estonian: • veenide värvuse muutumine ja/või veenide laienemine
English: Manufacturer Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom
Estonian: Tootja Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, Ühendkuningriik
English: • At the request of the European Medicines Agency; Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Estonian: • kui muudetakse riskijuhtimissüsteemi, eriti kui saadakse uut teavet, mis võib oluliselt mõjutada riski/kasu suhet, või kui saavutatakse oluline (ravimiohutuse või riski minimeerimise) eesmärk.
English: Ten percent of patients have a mean terminal elimination halflife greater than 100 hours.
Estonian: Kümnel protsendil patsientidest on eliminatsiooni keskmine poolväärtusaeg üle 100 tunni.
English: CYP2D6 inducers and inhibitors.
Estonian: CYP2D6 indutseerijad ja inhibiitorid
English: Children and Adolescents (aged 1 month to 17 years) The doctor will decide the dose, depending on bodyweight, however the maximum dose is 1500 micrograms.
Estonian: Lapsed ja noorukid (vanuses 1 kuust kuni 17 aastani) Arst otsustab annuse üle olenevalt kehakaalust, kuid maksimaalne annus on 1500 mikrogrammi.
English: Volume of distribution c, d,
Estonian: Jaotusmaht c, d
English: Each vial contains one dose.
Estonian: Üks viaal sisaldab ühte annust.
English: Via Fosse Ardeatine, 2, 20060, Liscate (MI) Italy
Estonian: Via Fosse Ardeatine, 2, 20060, Liscate (MI) Itaalia
English: The following common or uncommon adverse reactions were reported for palonosetron, none were reported at a frequency of >1%.
Estonian: Palonosetrooni kasutamisel teatati järgmistest sagedatest või aeg-ajalt esinevatest kõrvaltoimetest, millest ükski ei esinenud sagedusega > 1%.
English: Palonosetron Hospira should be injected over 30 seconds.
Estonian: Palonosetron Hospira't tuleb süstida 30 sekundi vältel.
English: A specific thorough QT/QTc study was conducted in healthy volunteers for definitive data demonstrating the effect of palonosetron on QT/QTc (see section 5.1).
Estonian: Tervete vabatahtlikega viidi läbi spetsiaalne põhjalik QT/QTc uuring kindlate andmete saamiseks palonosetrooni toime kohta QT/QTc-intervallile (vt lõik 5.1).
English: The underlying mechanisms are not fully understood, but because of the high doses employed and since Palonosetron Hospira is intended for single application in humans, these findings are not considered relevant for clinical use.
Estonian: Selle aluseks olevatest mehhanismidest ei saada täiesti aru, ent kuna kasutati suuri annuseid ja kuna Palonosetron Hospira on inimestel ette nähtud ühekordseks manustamiseks, ei loeta neid leide kliiniliselt asjakohasteks.
English: The study was designed to show non-inferiority.
Estonian: b Uuringu eesmärk oli näidata mittehalvemust.
English: 10 μg/kg
Estonian: 3,0 µg/kg 10 µg/kg
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.
Estonian: Kui te olete rase, imetate või arvate end olevat rase või kavatsete rasestuda, pidage enne selle ravimi kasutamist nõu oma arsti või apteekriga.
English: Pfizer Service Company BVBA, Hoge Wei 10, 1930 Zaventem, Belgium
Estonian: Pfizer Service Company BVBA, Hoge Wei 10, 1930 Zaventem, Belgia
English: Palonosetron at the recommended dose is widely distributed in the body with a volume of distribution of approximately 6.9 to 7.9 l/kg.
Estonian: Soovituslikus annuses palonosetroon jaotub kehas laialdaselt jaotusruumalaga ligikaudu 6,9...7,9 l/kg.
English: Do not use this medicine after the expiry date which is stated on the vial and carton after ‘EXP'.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud viaalil ja karbil pärast „Kõlblik kuni”.
English: Single use only, any unused solution should be discarded.
Estonian: Ainult ühekordseks kasutamiseks, kogu kasutamata jäänud lahus tuleb hävitada.
English: Hypokalemia and hypomagnesemia should be corrected prior to 5-HT3 -antagonist administration.
Estonian: Hüpokaleemia ja hüpomagneseemia tuleb enne 5-HT3-antagonisti manustamist korrigeerida.
English: • if you have a personal or family history of alterations in heart rhythm (QT prolongation);
Estonian: • kui teil või teie sugulasel on esinenud muutusi südamerütmis (QT-intervalli pikenemine);
English: Other medicines and Palonosetron Hospira
Estonian: Muud ravimid ja Palonosetron Hospira
English: • sleepiness or trouble sleeping
Estonian: • unetus või uinumisraskused
English: Avara Liscate Pharmaceutical Services S.p.A., Via Fosse Ardeatine, 2, 20060, Liscate (MI), Italy
Estonian: Avara Liscate Pharmaceutical Services S.p.A., Via Fosse Ardeatine, 2, 20060, Liscate, (MI), Itaalia
English: Serotonergic Drugs (e.g. SSRIs and SNRIs)
Estonian: Serotoninergilised ravimid (nt SSRId ja SNRId)
English: Pharmacotherapeutic group: Antiemetics and antinauseants, serotonin (5HT3) antagonists, ATC code: A04AA05
Estonian: Farmakoterapeutiline rühm: oksendamis- ja iiveldusvastased ained, serotoniini (5-HT3) antagonistid, ATC-kood: A04AA05.
English: If you are pregnant or think you might be, your doctor will not administer Palonosetron Hospira to you unless it is clearly necessary.
Estonian: Kui te olete rase või arvate end olevat rase, manustab arst teile Palonosetron Hospira't vaid sel juhul, kui see on hädavajalik.
English: Although comparative efficacy of palonosetron in multiple cycles has not been demonstrated in controlled clinical studies, 875 patients enrolled in the three phase 3 trials continued in an open label safety study and were treated with palonosetron 750 micrograms for up to 9 additional cycles of chemotherapy.
Estonian: Kuigi kontrollitud kliinilistes uuringutes ei ole tõendatud palonosetrooni võrreldavat efektiivsust mitmes tsüklis, osalesid kolmes 3. faasi uuringus osalenud 875 patsienti ka neile järgnenud avatud ohutuseuuringus ja neid raviti palonosetrooni annusega 750 mikrogrammi veel kuni 9 keemiaravi tsükli jooksul.
English: It is not known whether Palonosetron Hospira will cause any harmful effects when used during pregnancy.
Estonian: Ei ole teada, kas Palonosetron Hospira kasutamine raseduse ajal avaldab kahjulikku mõju.
English: HOSPIRA Enterprises B.V., Randstad 22-11, 1316 BN Almere, The Netherlands
Estonian: HOSPIRA Enterprises B.V., Randstad 22-11, 1316 BN Almere, Holland
English: • if you have acute bowel obstruction or a history of repeated constipation;
Estonian: • kui teil on äge soolesulgus või on esinenud korduvaid kõhukinnisusi;
English: A doctor or nurse will normally inject Palonosetron Hospira about 30 minutes before the start of chemotherapy.
Estonian: Arst või õde süstib Palonosetron Hospira't tavaliselt ligikaudu 30 minutit enne keemiaravi alustamist.
English: Adults Cancer Patients
Estonian: Vähiga täiskasvanud patsiendid
English: Allergic reactions to Palonosetron Hospira.
Estonian: Allergilised reaktsioonid Palonosetron Hospira suhtes.
English: There are limited data on the use of palonosetron in the prevention of nausea and vomiting in children under 2 years of age.
Estonian: Andmed palonosetrooni kasutamise kohta iivelduse ja oksendamise ennetamiseks alla 2 aasta vanustel lastel on piiratud.
English: • SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine.
Estonian: • SNRId (serotoniini ja noradrenaliini tagasihaarde inhibiitorid), mida kasutatakse depressiooni ja/või ärevuse raviks, sealhulgas venlafaksiin, duloksetiin.
English: • if you have an imbalance of certain minerals in your blood such as potassium and magnesium which has not been treated.
Estonian: • kui teie veres on teatavate mineraalainete, näiteks kaaliumi ja magneesiumi tasakaalu häired,
English: Efficacy after palonosetron 10 μg/kg compared to palonosetron 3 μg/kg was 54.1% and 37.1% respectively.
Estonian: Efektiivsus palonosetrooni 10 mikrogrammi/kg manustamise järel võrreldes palonosetrooniga 3 mikrogrammi/kg oli vastavalt 54,1% ja 37,1%.
English: Palonosetron Hospira will be given as a slow infusion into a vein.
Estonian: Palonosetron Hospira't manustatakse aeglase infusioonina veeni.
English: In clinical studies the following adverse reactions (ARs) were observed as possibly or probably related to palonosetron.
Estonian: Kliinilistes uuringutes täheldati järgmisi võimalikult või tõenäoliselt palonosetrooniga seotud kõrvaltoimeid.
English: When the dose was increased from 10 μg/kg to 20 μg/kg a dose-proportional increase in mean AUC was observed.
Estonian: Annuse suurendamisel tasemelt 10 mikrogrammi/kg tasemeni 20 mikrogrammi/kg täheldati keskmise AUC annusega proportsionaalset suurenemist.
English: 0 - 24 hours 24 - 120 hours 0 - 120 hours Complete Control (Complete Response and No More Than Mild Nausea)
Estonian: 0...24 tundi 24...120 tundi 0...120 tundi Täielik kontroll (täielik reageerimine ja vaid kerge iiveldus)
English: The study demonstrated no effect on QT/QTc interval duration as well as any other ECG interval at doses up to 2.25 mg. No clinically significant changes were shown on heart rate, atrioventricular (AV) conduction and cardiac repolarisation.
Estonian: Uuring ei näidanud toimet QT/QTc-intervalli ega muu EKG-intervalli kestusele kuni annuseni 2,25 mg. Kliiniliselt olulisi muutusi südame löögisageduses, atrioventrikulaarses (AV) ülejuhtes ja südame repolarisatsioonis ei esinenud.
English: Median half-life was 29.5 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 μg/kg.
Estonian: Mediaanne poolväärtusaeg oli vanuserühmades üldiselt 29,5 tundi ja oli vanuserühmiti varieeruv vahemikus ligikaudu 20 kuni 30 tundi pärast 20 mikrogrammi/kg manustamist.
English: • if you are using Palonosetron Hospira in addition to other medicines that may induce an abnormal heart rhythm such as amiodarone, nicardipine, quinidine, moxifloxacin, erythromycin,
Estonian: • kui kasutate Palonosetron Hospira't lisaks ravimitele, mis võivad põhjustada südame rütmihäireid, nt amiodaroon, nikardipiin, kinidiin, moksifloksatsiiin, erütromütsiin, haloperidool,
English: The signs may include swelling of the lips, face, tongue or throat, having difficulty breathing or collapsing, you could also notice an itchy, lumpy rash (hives), burning or pain at the site of injection.
Estonian: Nähtude hulka võivad kuuluda huulte, näo, keele või kõri turse, hingamisraskused või kollaps, võite täheldada ka sügelevat mügarlikku löövet (nahapõletikku), põletustunne või valu süstekohal.
English: Palonosetron Hospira belongs to a group of medicines known as serotonin (5HT3) antagonists.
Estonian: Palonosetron Hospira kuulub ravimirühma, mida nimetatakse serotoniini (5HT3) antagonistideks.
English: Dialysis studies have not been performed, however, due to the large volume of distribution, dialysis is unlikely to be an effective treatment for Palonosetron Hospira overdose.
Estonian: Dialüüsi ei ole uuritud, kuid suure jaotusruumala tõttu ei ole dialüüs Palonosetron Hospira'ga üleannustamise korral tõenäoliselt efektiivne ravi.
English: Important information about some of the ingredients of Palonosetron Hospira This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium- free'.
Estonian: Oluline teave mõningate Palonosetron Hospira koostisosade kohta See ravim sisaldab vähem kui 1 mmol naatriumi (23 mg) viaali kohta, s.t on sisuliselt naatriumivaba.
English: Available in packs of 1 vial containing 5 ml of solution.
Estonian: Saadaval pakendites, mis sisaldavad 1 viaali 5 ml lahusega.
English: Given the pre-specified noninferiority margin of -10%, the stratum adjusted Mantel-Haenszel statistical non-inferiority confidence interval for the difference in the primary endpoint, complete response (CR), was [-10.5, 1.7%], therefore non-inferiority was not demonstrated.
Estonian: Võttes arvesse eelnevalt kehtestatud mittehalvemusvaru -10%, oli esmase tulemusnäitaja, täielike ravivastuste (CR) vahe, kihiga kohandatud Manteli-Haenszeli statistiline mittehalvemuse usaldusintervall [-10,5, 1,7%], seega mittehalvemust ei tõestatud.
English: What Palonosetron Hospira looks like and contents of the pack Palonosetron Hospira solution for injection is a clear, colourless solution and is supplied in a pack of one Type I glass vial with a chlorobutyl rubber stopper and aluminium cap, which contains 5 ml of the solution.
Estonian: Kuidas Palonosetron Hospira välja näeb ja pakendi sisu Palonosetron Hospira süstelahus on selge värvitu lahus ning on saadaval pakendis, mis sisaldab üht I tüüpi klaasist ja klorobutüülkummist korgi ning alumiiniumkaanega viaali 5 ml lahusega.
English: These were classified as common (≥1/100 to <1/10) or uncommon (≥1/1,000 to <1/100).
Estonian: Need liigitati sagedasteks (≥ 1/100 kuni < 1/10) või aeg-ajalt esinevateks (≥ 1/1000 kuni < 1/100).
English: Dolasetron 100 milligrams (n= 191)
Estonian: Dolasetroon 100 milligrammi (n = 191)
English: This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium-free'.
Estonian: Ravim sisaldab vähem kui 1 mmol naatriumi (23 mg) viaali kohta, s.t on sisuliselt naatriumivaba.